PD-1/PD-L1 blockade is efficacious in tumor immunotherapy but can trigger AEs because checkpoint inhibition may induce systemic immune overactivation, resulting in autoimmune-like reactions across multiple organs. The gene discussed is PDCD1; the disease is neoplasm.